Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
Daewon Pharmaceutical Co., Ltd.
🇰🇷
South Korea
Country
🇰🇷
South Korea
Ownership
Public
Established
1958-01-07
Employees
1.2K
Market Cap
-
Website
http://www.daewonpharm.com
Clinical Trials
Related News
Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients
Phase 2
Conditions
Acute and Chronic Gastric Inflammation Patients
Interventions
Drug: Placebo
Drug: DW-3101_150mg
Drug: DW-3101_300mg
Drug: DW-3101_600mg
Subscribe
First Posted Date
2015-03-11
Last Posted Date
2016-10-12
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02386007
Subscribe
Study of Freefol-MCT PKPD in Healthy Volunteers
Conditions
Healthy
Subscribe
First Posted Date
2015-03-10
Last Posted Date
2016-10-10
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
60
Registration Number
NCT02384720
Subscribe
Phase 1 Clinical Trial of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DW340
Subscribe
First Posted Date
2015-03-05
Last Posted Date
2016-10-12
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
24
Registration Number
NCT02380976
Subscribe
Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients
Phase 3
Completed
Conditions
Chronic Back Pain
Interventions
Drug: DW-330SR2
Drug: Pelubiprofen
Subscribe
First Posted Date
2015-03-02
Last Posted Date
2016-10-10
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
166
Registration Number
NCT02375633
Subscribe
A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients
Phase 2
Conditions
Hypercholesterolemia
Interventions
Drug: DW-3102
Subscribe
First Posted Date
2015-02-23
Last Posted Date
2016-10-10
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
64
Registration Number
NCT02368613
Subscribe
Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects
Phase 1
Completed
Conditions
Healthy
Interventions
Drug: DW330SR 45mg
Drug: DW1030 75mg
Subscribe
First Posted Date
2014-02-25
Last Posted Date
2015-03-30
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Registration Number
NCT02071381
Locations
🇰🇷
Asan Medical Center IRB, Seoul, Korea, Republic of
Subscribe
Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients
Phase 3
Completed
Conditions
Acute Back Pain
Interventions
Drug: Myonal Tab.(eperisone HCl) 50mg
Drug: DW-1030(eperisone HCl) 75mg
Drug: Placebo drug of DW-1030
Drug: Placebo drug of Myonal Tab.
Subscribe
First Posted Date
2014-01-20
Last Posted Date
2016-10-12
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
242
Registration Number
NCT02040415
Subscribe
Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Acute Toothache Patients After Teeth Extraction Surgery
Phase 3
Completed
Conditions
Acute Toothache Patients Above Moderate Pain After Teeth Extraction Surgery
Interventions
Drug: Tramadol hydrochloride/Acetaminophen Tab.
Drug: Tramadol hydrochloride/Acetaminophen SR Tab.
Subscribe
First Posted Date
2013-08-12
Last Posted Date
2016-10-12
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
240
Registration Number
NCT01920386
Subscribe
Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects
Phase 1
Completed
Conditions
Healthy Males
Interventions
Drug: Pelubiprofen IR (Pelubiprofen 30mg) TID
Drug: Pelubiprofen SR (Pelubiprofen 45 mg) BID
Subscribe
First Posted Date
2013-06-05
Last Posted Date
2014-01-14
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Registration Number
NCT01870102
Subscribe
Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients
Phase 3
Completed
Conditions
Pelubiprofen
Celebrex
Rheumatoid Arthritis
Interventions
Drug: Pelubiprofen 30 mg
Drug: Celebrex 200 mg
Subscribe
First Posted Date
2013-02-01
Last Posted Date
2013-08-09
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
120
Registration Number
NCT01781702
Subscribe
Prev
1
2
3
4
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy